JP2016512511A - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤 Download PDF

Info

Publication number
JP2016512511A
JP2016512511A JP2016500985A JP2016500985A JP2016512511A JP 2016512511 A JP2016512511 A JP 2016512511A JP 2016500985 A JP2016500985 A JP 2016500985A JP 2016500985 A JP2016500985 A JP 2016500985A JP 2016512511 A JP2016512511 A JP 2016512511A
Authority
JP
Japan
Prior art keywords
tert
butoxy
methylpyrazolo
pyrimidin
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016500985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512511A5 (https=
Inventor
ビー・ナラシムフル・ナイドゥ
マノジ・ペイテル
ケビン・ピース
ワン・ジョンギュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016512511A publication Critical patent/JP2016512511A/ja
Publication of JP2016512511A5 publication Critical patent/JP2016512511A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016500985A 2013-03-13 2014-03-10 ヒト免疫不全ウイルス複製の阻害剤 Ceased JP2016512511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779858P 2013-03-13 2013-03-13
US61/779,858 2013-03-13
PCT/US2014/022501 WO2014164467A1 (en) 2013-03-13 2014-03-10 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2016512511A true JP2016512511A (ja) 2016-04-28
JP2016512511A5 JP2016512511A5 (https=) 2017-04-13

Family

ID=50478938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500985A Ceased JP2016512511A (ja) 2013-03-13 2014-03-10 ヒト免疫不全ウイルス複製の阻害剤

Country Status (5)

Country Link
US (1) US9580431B2 (https=)
EP (1) EP2970298A1 (https=)
JP (1) JP2016512511A (https=)
CN (1) CN105189511B (https=)
WO (1) WO2014164467A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US9975906B2 (en) 2014-05-16 2018-05-22 Shionogi & Co., Ltd. Tricyclic heterocycle derivatives having HIV replication inhibitory effect
TWI700284B (zh) 2015-05-29 2020-08-01 日商塩野義製藥股份有限公司 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
US20180170903A1 (en) 2015-07-06 2018-06-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
RU2018102554A (ru) 2015-07-08 2019-08-08 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
RU2018103031A (ru) 2015-07-09 2019-08-09 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
US20180170904A1 (en) 2015-07-09 2018-06-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
KR20180035910A (ko) 2015-08-07 2018-04-06 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
WO2017025913A1 (en) 2015-08-10 2017-02-16 VIIV Healthcare UK (No.5) Limited Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
TWI657086B (zh) 2015-08-11 2019-04-21 英商Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物
US10214516B2 (en) 2015-08-12 2019-02-26 VIIV Healthcare UK (No.5) Limited 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
CN108137553A (zh) 2015-08-12 2018-06-08 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的5-(n-[6,5]-稠合双环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物
KR20180038047A (ko) 2015-08-20 2018-04-13 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
JP2019515000A (ja) 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
US10407410B2 (en) 2016-05-11 2019-09-10 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20190152957A1 (en) 2016-05-11 2019-05-23 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201835068A (zh) 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物
EP3565810A1 (en) 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US10234220B2 (en) * 2017-04-14 2019-03-19 Kent J. Myers Detachable box magazine with follower retraction member
CA3088347A1 (en) * 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiii.beta. inhibitors
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020081856A1 (en) * 2018-10-18 2020-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of hiv-1 nef for the treatment of hiv disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076765A1 (en) * 2009-12-23 2011-06-30 Katholieke Universiteit Leuven Novel antiviral compounds
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2012065963A2 (en) * 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds
WO2013025584A1 (en) * 2011-08-18 2013-02-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401436D0 (en) 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
HRP20000495B1 (en) 1998-02-04 2005-12-31 Banyu Pharmaceutical Co. N-acyl cyclic amine derivatives
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
CA2681695A1 (en) 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
ATE541841T1 (de) 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
ES2402322T3 (es) 2007-11-15 2013-04-30 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
ES2463720T3 (es) 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
EP2215298B1 (en) 2007-11-23 2014-03-26 Koninklijke Philips N.V. Compartment
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
EP2640729B1 (en) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibitors of hiv replication
US9034882B2 (en) * 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076765A1 (en) * 2009-12-23 2011-06-30 Katholieke Universiteit Leuven Novel antiviral compounds
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2012065963A2 (en) * 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds
WO2013025584A1 (en) * 2011-08-18 2013-02-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
CN105189511B (zh) 2017-05-24
US9580431B2 (en) 2017-02-28
WO2014164467A1 (en) 2014-10-09
EP2970298A1 (en) 2016-01-20
CN105189511A (zh) 2015-12-23
US20160016960A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
JP2016512511A (ja) ヒト免疫不全ウイルス複製の阻害剤
CN105189503B (zh) 人免疫缺陷病毒复制的抑制剂
US8629276B2 (en) Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) Inhibitors of human immunodeficiency virus replication
US8791108B2 (en) Inhibitors of human immunodeficiency virus replication
AU2013302873A1 (en) Inhibitors of human immunodeficiency virus replication
CN105189510B (zh) 人免疫缺陷病毒复制的抑制剂
CN111818917A (zh) 大环mcl-1抑制剂和使用方法
EP3186254B1 (en) Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
TW202535873A (zh) 抗病毒吡唑并吡啶酮化合物
JP6268656B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
WO2015126737A1 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015123182A1 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3114129A1 (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
JP2018519348A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
HK40069881A (zh) 抗病毒吡唑并吡啶酮化合物
HK40069881B (zh) 抗病毒吡唑并吡啶酮化合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171208

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171212

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180508

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180925